A Safety and Efficacy Study of Mycophenolate Mofetil and Rilonacept in Patients With Alcoholic Hepatitis
Status:
Completed
Trial end date:
2016-04-01
Target enrollment:
Participant gender:
Summary
This clinical trial will test two new therapies for the treatment of alcoholic hepatitis.
Patients who "respond" to the current standard of care therapy for alcoholic
hepatitis(corticosteroid/prednisolone therapy) after 1 week of treatment will be randomly
assigned to either continue on standard therapy, or, to begin treatment with rilonacept in
combination with standard therapy. Patients who are "non-responders" to the current standard
of care therapy after 1 week of treatment will be randomly assigned to standard of care or to
begin treatment with mycophenolate mofetil in combination with standard therapy. Patients
will be treated for a total of 4 weeks in this clinical trial. Patients will be followed for
up to five months after completing therapy (6 months total).
Phase:
Phase 2
Details
Lead Sponsor:
Southern California Institute for Research and Education Timothy Morgan, MD
Collaborators:
Los Angeles Biomedical Research Institute Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center National Institute on Alcohol Abuse and Alcoholism (NIAAA) Southern California Institute for Research and Education University of Southern California VA Long Beach Healthcare System